Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): A randomised, international, multicentre, double-blind, placebo-controlled trial
Lancet 2024;403(10429):850–859 doi 10.1016/S0140-6736(23)02650-8
This study by Rech, et al. shows that 6-month treatment with abatacept was associated with a decrease in MRI inflammation, clinical symptoms, and risk of RA development in participants at high risk. The effects of the intervention persist through a 1-year drug-free observation phase.
Patients with a history of joint pain who tested positive for anti-citrullinated protein antibodies were monitored for an 18-month period, with the first six months consisting of a treatment phase where patients were randomised 1:1 to abatacept or placebo. Patients were then observed in a 1-year drug-free observation period.
Keywords:
